Market News / Story
Glaukos Corporation (GKOS) Posts 3-Year Epioxa Phase 3 Extension Data
·
Glaukos reported long-term Phase 3 extension results for Epioxa in keratoconus, showing a sustained 1.9D Kmax improvement at 3 years and no serious adverse events in treated eyes. Material Details #DetailAI Analyst View1Sustained 1.9D Kmax improvement at 3yIndicates durable efficacy from a single treatment, supporting adoption and reimbursement.2No serious adverse events at 3yFavorable safety de-risks long-term use and could ease clinician uptake.329% gained ≥2 BCVA…